Fintel reports that on October 13, 2023, Wedbush maintained coverage of Astria Therapeutics (NASDAQ:ATXS) with a Outperform recommendation.
Analyst Price Forecast Suggests 290.55% Upside
As of October 5, 2023, the average one-year price target for Astria Therapeutics is 24.92. The forecasts range from a low of 18.18 to a high of $34.65. The average price target represents an increase of 290.55% from its latest reported closing price of 6.38.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Astria Therapeutics is 0MM. The projected annual non-GAAP EPS is -2.99.
What is the Fund Sentiment?
There are 175 funds or institutions reporting positions in Astria Therapeutics. This is an increase of 74 owner(s) or 73.27% in the last quarter. Average portfolio weight of all funds dedicated to ATXS is 0.14%, a decrease of 59.54%. Total shares owned by institutions increased in the last three months by 6.45% to 25,234K shares. 
The put/call ratio of ATXS is 0.34, indicating a bullish outlook.
What are Other Shareholders Doing?
Perceptive Advisors holds 2,189K shares representing 7.81% ownership of the company. No change in the last quarter.
Fairmount Funds Management holds 1,901K shares representing 6.78% ownership of the company. No change in the last quarter.
Deep Track Capital holds 1,697K shares representing 6.05% ownership of the company. In it's prior filing, the firm reported owning 1,817K shares, representing a decrease of 7.02%. The firm decreased its portfolio allocation in ATXS by 34.04% over the last quarter.
Vivo Capital holds 1,681K shares representing 6.00% ownership of the company. No change in the last quarter.
Driehaus Capital Management holds 1,456K shares representing 5.19% ownership of the company. In it's prior filing, the firm reported owning 1,433K shares, representing an increase of 1.58%. The firm decreased its portfolio allocation in ATXS by 42.76% over the last quarter.
Astria Therapeutics Background Information
(This description is provided by the company.)
Astria Therapeutics’ dedicated and passionate team is devoted to bringing life-changing therapies to patients and families impacted by HAE and rare and niche allergic and immunological diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
